Skip to main content

Table 1 Characteristics of patients who were either administered tocilizumab at different intervals or methotrexate

From: A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis

  3-Week group (n = 10) 4-Week group (n = 10) 5-Week group (n = 10) Control group (n = 10) P value
Sex (female, n/total n, %) 9/10, 90% 9/10, 90% 8/10, 80% 8/10, 80% 0.85
Age (years) 55.3 (14.8) 65.0 (9.9) 62.0 (10.6) 66.7 (11.0) 0.27
RA duration (months) 101.5 (86.5) 68.5 (74.6) 116.5 (92.5) 81.9 (78.7) 0.35
Tocilizumab duration (months) 27.1 (20.7) 11.9 (9.2) 39.6 (12.1) - <0.01*
RF positive (n, %) 7/10, 70% 9/10, 90% 9/10, 90% 5/10, 50% 0.12
ACPA positive (n, %) 5/8, 63% 7/10, 70% 8/10, 80% 6/10, 60% 0.77
MTX use (n, %) 4/10, 40% 6/10, 60% 4/10, 40% 10/10, 100% 0.03*
MTX dose (mg/week) 7.5 (4.1) 8.3 (2.0) 4.4 (0.9) 9.0 (3.6) 0.07
CRP (mg/dl) 0.01 (0.02) 0.01 (0.02) 0.03 (0.03) 0.13 (0.10) <0.01*
ESR (mm/h) 6.0 (4.7) 6.6 (5.6) 12.3 (14.4) 22.2 (12.8) <0.01*
CDAI 5.2 (1.3-8.1) 1.7 (0.1-7.9) 1.7 (0.1-5.8) 3.6 (0.2-6.3) 0.07
HAQ-DI 1.1 (0.8) 0.5 (0.6) 0.3 (0.5) 0.5 (0.5) 0.06
  1. Values are expressed as mean ± standard deviation (SD) unless stated otherwise
  2. RA rheumatoid arthritis, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibody, MTX methotrexate, CRP C-reactive protein, ESR erythrocyte sedimentation rate, CDAI clinical disease activity index, HAQ-DI health assessment questionnaire disability index
  3. *P < 0.05